Merck (MRK) Provides Update on KEYTRUDA Indication in Metastatic Small Cell Lung Cancer in the US
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company is voluntarily withdrawing the U.S. indication for KEYTRUDA (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The withdrawal of this indication was done in consultation with the U.S. Food and Drug Administration (FDA), and Merck is working to complete this process over the coming weeks. This decision does not affect other indications for KEYTRUDA, Merck’s anti-PD-1 therapy.
This accelerated approval for KEYTRUDA was granted in June 2019 based on tumor response rate and durability of response data from KEYNOTE-158 (cohort G) and KEYNOTE-028 (cohort C1). Continued approval for this indication was contingent upon completion of the post-marketing requirement establishing superiority of KEYTRUDA as determined by overall survival (OS). As announced in Jan. 2020, KEYNOTE-604, the confirmatory Phase 3 trial for this indication, met one of its dual primary endpoints of progression-free survival but did not reach statistical significance for the other primary endpoint of OS.
Merck’s consultation with the FDA on this withdrawal is part of an industry-wide evaluation of indications based on accelerated approvals that have not yet met their post-marketing requirements. Merck is notifying health care professionals about this withdrawal. Patients being treated with KEYTRUDA for their metastatic SCLC should discuss their care with their health care provider.
“The accelerated pathways created by the FDA have been integral to the remarkable progress in oncology care over the past five years and have helped many cancer patients with advanced disease, including small cell lung cancer, access new treatments,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “KEYTRUDA remains a foundational treatment for certain patients with metastatic non-small cell lung cancer. We will continue to rigorously evaluate the benefits of KEYTRUDA in small cell lung cancer and other types of cancer, in pursuit of Merck’s mission to save and improve lives.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
- CorMedix (CRMD) Has Meeting With FDA on DefenCath Catheter Lock Solution NDA
- Moderna (MRNA) announces interim Phase 1 data from RSV vaccine candidate and new 7-month interim Phase 2 data from its CMV vaccine candidate